Home
Search

Press Releases

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Featured Press Releases
Do You Know a Game-Changer in the Bioeconomy?…
The Biotechnology Innovation Organization today announced the opening of nominations for two awards to honor significant leaders driving cutting-edge, sustainable breakthroughs in the fields of agriculture and the environment. BIO will accept…
Learn more
WTO Decision on Waiving Intellectual Property…
Dr. Michelle McMurry-Heath, president & CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to a decision by the World Trade Organization (WTO) Ministerial Conference (MC12) to endorse a COVID-19…
Learn more
BIO Elects New Board Directors and Re-Elects…
The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee directors for the 2022-2023 term. BIO’s Board elections took place Monday, June 13 during the 2022 BIO International Convention…
Learn more
All Press Releases
  • Show All
Search
Results
BIO Statement on New PDUFA Package
May 4, 2022
The House Energy & Commerce Committee today unveiled a new package for the Prescription Drug User Fee Act (PDUFA). After the release, BIO’s Chief Science Officer, Cartier Esham, made the following remarks:  "For more than thirty years, the…
BIO Statement on USTR Special 301 Report
April 29, 2022
 USTR this week released its 2022 Special 301 Report. BIO, after reviewing the report, released the following statement: We welcome USTR’s efforts to address IP-related concerns for U.S.-based biotech enterprises in China, especially…
New Ways & Means health package a "critical building block for future biotech innovation"
April 19, 2022
In an effort to secure medical supply chains and invest in the cures and treatment of the future, members of the House Ways and Means committee this week reintroduced major legislation that "ensures a healthier future for all Americans." BIO…
CMS Decision is an Enormous Setback for Alzheimer's Patients and a Dangerous Infringement on FDA's Scientific Autonomy
April 8, 2022
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS’s) National Coverage Determination (NCD) to…
New Season of Biotech Podcast Builds Trust in Science
March 22, 2022
Washington, D.C.– The Biotechnology Innovation Organization (BIO) today premieres its new season of the I AM BIO podcast, which tells powerful stories across the biotechnology industry and how it heals, fuels, and feeds our world. The season…
BIO Statement on Reports of a Proposed Deal on COVID-19 Vaccine IP Rights Waiver
March 16, 2022
John Murphy, Chief Policy Officer at the Biotechnology Innovation Organization (BIO), released the following statement regarding reports of a proposed deal on a Covid-19 vaccine intellectual property rights waiver: “While we have seen the reported…
BIO Statement on Russia's Decision To Legalize Patent Theft
March 11, 2022
“Retaliation of this kind will only serve to isolate Russian science and technology from the international mainstream. At the end of the day those who will be most hurt by this decision will not be innovative global companies, but Russian patients,…
BIO Joins Efforts to Aid in Humanitarian Relief in Ukraine
March 2, 2022
The following statement can be attributed to BIO’s President and CEO Dr. Michelle McMurry-Heath in response to the ongoing conflict in Ukraine and the organization’s efforts to help in humanitarian relief: “The conflict in Ukraine and violence…
BIO Encourages Science-based Oversight for Animal and Plant Biotech as Dr. Califf Takes Helm at FDA
February 15, 2022
The following statement may be attributed to BIO's Vice President for Agriculture and Environment Sarah Gallo:  “BIO looks forward to working with a proven leader like Dr. Califf as he takes the helm at FDA. Dr. Califf will lead an…
BIO Statement on Confirmation of Dr. Califf to Lead FDA
February 15, 2022
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), made the following statement after Dr. Robert Califf was confirmed by the Senate to lead the Food and Drug Administration (FDA): “We congratulate Dr…
gooddaybio-cover-final
Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy. 

Sign Up Today